NYSE:RMEDRA Medical Systems Stock Price, Forecast & News

RA Medical Systems' stock was trading at $1.2563 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RMED stock has decreased by 53.8% and is now trading at $0.5799. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RA Medical Systems in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for RA Medical Systems.

RA Medical Systems is scheduled to release its next quarterly earnings announcement on Wednesday, November 25th 2020. View our earnings forecast for RA Medical Systems.

RA Medical Systems Inc (NYSE:RMED) announced its earnings results on Wednesday, May, 13th. The company reported ($0.56) EPS for the quarter, missing the Zacks' consensus estimate of ($0.34) by $0.22. The firm earned $1.37 million during the quarter, compared to analyst estimates of $1.51 million. RA Medical Systems had a negative return on equity of 130.46% and a negative net margin of 732.37%. View RA Medical Systems' earnings history.

4 brokers have issued 1-year price targets for RA Medical Systems' stock. Their forecasts range from $1.00 to $3.00. On average, they expect RA Medical Systems' share price to reach $1.75 in the next twelve months. This suggests a possible upside of 201.8% from the stock's current price. View analysts' price targets for RA Medical Systems.

Press coverage about RMED stock has trended extremely positive on Thursday, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. RA Medical Systems earned a news sentiment score of 5.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutRA Medical Systems.

RA Medical Systems saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 196,700 shares, an increase of 108.1% from the April 30th total of 94,500 shares. Based on an average daily volume of 104,900 shares, the short-interest ratio is currently 1.9 days. Currently, 2.4% of the shares of the company are short sold. View RA Medical Systems' Current Options Chain.

Some companies that are related to RA Medical Systems include Atossa Genetics (ATOS), DarioHealth (DRIO), Biostage (BSTG), Delcath Systems (DCTH), Interpace Diagnostics Group (IDXG), Titan Medical (TMDI), Endologix (ELGX), Avinger (AVGR), Hypertension Diagnostics (HDII), Dynatronics (DYNT), Sintx Technologies (SINT), Encision (ECIA), Obalon Therapeutics (OBLN), Invivo Therapeutics (NVIV) and Lianluo Smart (LLIT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other RA Medical Systems investors own include Corbus Pharmaceuticals (CRBP), Vaxart (VXRT), Amarin (AMRN), Co-Diagnostics (CODX), Inovio Pharmaceuticals (INO), Agile Therapeutics (AGRX), Nabriva Therapeutics (NBRV), VBI Vaccines (VBIV), vTv Therapeutics (VTVT) and Advanced Micro Devices (AMD).

(RMED) raised $50 million in an initial public offering on Thursday, September 27th 2018. The company issued 3,300,000 shares at $14.00-$16.00 per share. Piper Jaffray and Cantor served as the underwriters for the IPO and SunTrust Robinson Humphrey, Nomura and Maxim Group were co-managers.

RA Medical Systems trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMED."

RA Medical Systems' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Principal Financial Group Inc. (3.53%) and Bourne Lent Asset Management Inc. (1.53%). Company insiders that own RA Medical Systems stock include Andrew C Jackson, Dean Irwin, Jeffrey J Kraws, Jonathan Will Mcguire, Martin Burstein and William R Enquist. View institutional ownership trends for RA Medical Systems.

RMED stock was sold by a variety of institutional investors in the last quarter, including Principal Financial Group Inc.. Company insiders that have sold RA Medical Systems company stock in the last year include Andrew C Jackson, Dean Irwin, Jeffrey J Kraws, and Martin Burstein. View insider buying and selling activity for RA Medical Systems.

RMED stock was purchased by a variety of institutional investors in the last quarter, including Bourne Lent Asset Management Inc.. Company insiders that have bought RA Medical Systems stock in the last two years include Jonathan Will Mcguire, and William R Enquist. View insider buying and selling activity for RA Medical Systems.

Shares of RMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RMED stock can currently be purchased for approximately $0.58.

RA Medical Systems has a market capitalization of $8.06 million and generates $7.20 million in revenue each year. The company earns $-56,960,000.00 in net income (profit) each year or ($4.33) on an earnings per share basis. RA Medical Systems employs 95 workers across the globe.

The official website for RA Medical Systems is www.ramed.com.

RA Medical Systems' mailing address is 2070 Las Palmas Drive, Carlsbad CA, 92011. The company can be reached via phone at 760-804-1648 or via email at [email protected]